Dr. Elana Bernstein, a specialist in Systemic Sclerosis, discusses lung disease in SS, including symptoms, diagnosis, and how it affects the lungs with topics like pulmonary hypertension and interstitial lung disease. She shares insights on screening, management strategies, and the latest research in the field.
Early diagnosis of systemic sclerosis is challenging due to varied initial symptoms, such as skin thickening and hand stiffness.
Systemic sclerosis treatment is personalized, with medications like mycophenolate mofetil considered first-line for skin and lung involvement.
Deep dives
Identifying Systemic Sclerosis Symptoms
Patients with systemic sclerosis can present with various initial symptoms, such as rainodes, hand stiffness, skin thickening, and telengioectases. These symptoms can manifest over a range of time, making early diagnosis challenging. Renal symptoms often precede other manifestations, highlighting the significance of recognizing non-renal signs for disease duration definition.
Diagnosing Systemic Sclerosis
The diagnosis of systemic sclerosis involves a comprehensive approach that combines clinical examination, serological evaluation, and meticulous attention to symptoms and physical findings. Key diagnostic tools include a detailed history, nail fold capillaroscopy, pulmonary and cardiac assessments for signs like crackles, digital ulcers, and other systemic sclerosis-related manifestations. Serological tests like ANA and specific systemic sclerosis-related autoantibodies are crucial diagnostic components.
Treatment Strategies for Systemic Sclerosis
Systemic sclerosis treatment strategies are intricately tailored based on individual patient manifestations and disease progression. While medications like mycophenolate mofetil (MMF) are considered first-line for skin and interstitial lung involvement, the management approach for each patient varies. Therapeutic decisions involve discussing risks, benefits, and potential side effects to optimize patient outcomes.
Future Directions and Research in Systemic Sclerosis
The evolving landscape of systemic sclerosis management holds promise for more effective therapies that extend beyond stabilizing diseases to achieving improvement of symptoms and functional outcomes. Personalized medicine approaches, enhanced by biomarkers predicting treatment responses, aim to revolutionize systemic sclerosis care. Ongoing clinical trials, like the platform conquest study and emerging immunosuppressive and CAR T-cell therapies, underscore the continual pursuit of better systemic sclerosis management strategies.
Expert researcher and clinician, Dr. Elana Bernstein, is our guest this week as we dive into lung disease brought on by Systemic Sclerosis (SS). We discuss symptoms, diagnosis, how systemic sclerosis affects the lungs, including pulmonary hypertension and interstitial lung disease. Dr. Bernstein, who has dedicated her career to improving patient outcomes in systemic sclerosis, explains her approach to screening for lung disease, plus the latest research and questions that need to be answered.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode